Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Inclusion Criteria: * Pathologically confirmed non-small cell lung cancer after surgical resection * Stage II-IIIA disease according to 7th edition of TNM staging * Positive EGFR gene mutation (19/21) * ECOG 0-1 * At least 1-year life expectancy * Adequate organ function Exclusion Criteria: * Previous systemic anti-tumor therapy, including chemotherapy or targeted therapy(Including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc * Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * Pneumonectomy of right lung * Any unresolved chronic toxicity from previous anticancer therapy * Allergic to study drug